
"Health wise I am feeling great. I am a big supporter of trials - it allows new treatments and drugs to be brought in.”
This trial was looking at chemotherapy for prostate cancer that had spread and was no longer responding to hormone therapy.
The trial compared 2 different ways of giving the chemotherapy drug docetaxel with another chemotherapy drug, mitoxantrone.
The trial team found that having docetaxel was better than mitoxantrone for men with advanced prostate cancer.
This trial recruited 1,006 men. They were put in to 1 of 3 treatment groups
The researchers looked at how well the men’s pain was controlled, their quality of life, their PSA blood level and how long they lived for. In all cases those who had docetaxel had better results than those who had mitoxantrone.
For the men having docetaxel every 3 weeks the results were
For the men having docetaxel once a week
For the men having mitoxantrone
On average, men in both of the docetaxel groups lived longer than the men in the mitoxantrone group. And the men who had docetaxel every 3 weeks on average lived the longest.
The researchers concluded that treatment with docetaxel every 3 weeks was much better for men with advanced prostate cancer than mitoxantrone.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists () and published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Nick James
Aventis Pharma
Freephone 0808 800 4040
"Health wise I am feeling great. I am a big supporter of trials - it allows new treatments and drugs to be brought in.”